Announcement on Outline of the Q3 2025 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Key company executives participated in the event to engage with investors and address their questions. The announcement includes a summary of the main questions raised by investors and the company's responses.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Joincare Pharmaceutical Group Industry Co., Ltd. on 6ix
Earlier from Joincare Pharmaceutical Group Industry
- Announcement on Completion of Deregistration of the Special Account for Funds Raised through Rights Issue
- Announcement on the Election of by the Employee Meeting
- Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
- Announcement on Resolutions of the 10th Meeting of the 9th Board of Supervisors
- Announcement on Outline of the 2025 Semi-annual Performance Briefing
Later from Joincare Pharmaceutical Group Industry
- Indicative Announcement on Extension of the Six-month Duration of the Second Phase of the Medium-and Long-term Business Partner Shareholding Plan
- Announcement on the Inclusion of the Company’s Product in the National Medical Insurance Catalog
- Announcement on Obtaining Drug Registration Certificate for Maribavir Capsules (Yilikang®)
- Indicative Announcement on Acceptance of Marketing Authorization Application for Laikangchita Monoclonal Antibody Injection
- Announcement on Subsidiary Obtaining PIC/S GMP Certification
Follow Joincare Pharmaceutical Group Industry into a list and get an email when it puts out news.
Follow Joincare Pharmaceutical Group Industry